Traws Pharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 17
- Market Cap
- -
- Website
- http://www.trawspharma.com
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
- Conditions
- Solid Tumor
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01165905
- Locations
- 🇺🇸
Department of Medicine, University of California San Francisco, San Francisco, California, United States
🇺🇸Albert Einstein Cancer Center/Montefiore Medical Center, The Bronx, New York, United States
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
- Conditions
- Solid TumorsMalignant Neoplasmas
- Interventions
- Drug: ON 01910.Na
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01125891
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01049113
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Drug: ON 01910.Na
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01048619
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Drug: ON 01910.Na
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00906334
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic Syndrome
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Registration Number
- NCT00867061
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: ON 01910.Na and irinotecanDrug: ON 01910.Na and oxaliplatin
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00861328
- Locations
- 🇺🇸
Albert Einstein Cancer Center, The Bronx, New York, United States
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
- Conditions
- HepatomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00861783
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
- Conditions
- Ovarian Cancer
- Interventions
- Drug: ON 01910.Na
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00856791
- Locations
- 🇺🇸
St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Drug: ON 01910.Na
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00854945
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States